TapewireFind a company

person · Reporting owner

Halevy Gilead

Disclosed activity across 1 company

Tapewire entity
27824
SEC CIK
0001972184

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
COMPUGEN LTDCGEN · Entity 6149DirectorJuly 29, 2026July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COMPUGEN LTD

Report date July 29, 2026 · Filed July 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect18,907 Reported balance After 2026-07-29 transaction · row 1
1 source row

Row 1 · 2026-07-29 · Grant · Acquired 7,500 · Balance 18,907

F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2036-07-29Direct10,000 Reported balance After 2026-07-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-07-29 · Grant · Acquired 10,000 · Balance 10,000

F2: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

F2: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 29, 2026 Filed Jul 30, 2026 20:03 UTC COMPUGEN LTD CGEN · Entity 6149 GrantShare Option (right to buy) · Derivative 10,000 $0.00 Strike: $2.26 $0.00
Disclosure

SEC source: 0001178913-26-003711 · zk2635767.xml · derivative · entry 2

Halevy Gilead · CIK 0001972184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Ordinary Shares · 10,000 shares

Expires 2036-07-29

F2 · derivative.exercise_date: This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
July 29, 2026 Filed Jul 30, 2026 20:03 UTC COMPUGEN LTD CGEN · Entity 6149 GrantOrdinary Shares 7,500 $0.00 $0.00
Disclosure

SEC source: 0001178913-26-003711 · zk2635767.xml · nonDerivative · entry 1

Halevy Gilead · CIK 0001972184 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,907

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.